FDA approved Miltenyi Biotec’s CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from a matched related donor.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
